About: Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)
Creator	Ren, Lili Wang, Jianwei Xiao, Yan Guo, Li Wu, Chao Xu, Yan Jin, Qi Yang, Fan Chang, De Sharma, Lokesh Xiao, Meng Wang, Yingying Dela Cruz, Charles Wang, Linghang Yang, Siyuan Dang, Shengyuan Han, Lianlian Xu, Sheng-Yong Xu, Ying-Chun Yang, Qi-Wen Zhang, Lulu Zhu, Hua-Dong
Source	Medline; PMC
abstract	BACKGROUND: The emergence of coronavirus disease 2019 (COVID-19) is a major healthcare threat. The current method of detection involves a quantitative polymerase chain reaction (qPCR)–based technique, which identifies the viral nucleic acids when present in sufficient quantity. False-negative results can be achieved and failure to quarantine the infected patient would be a major setback in containing the viral transmission. We aim to describe the time kinetics of various antibodies produced against the 2019 novel coronavirus (SARS-CoV-2) and evaluate the potential of antibody testing to diagnose COVID-19. METHODS: The host humoral response against SARS-CoV-2, including IgA, IgM, and IgG response, was examined by using an ELISA-based assay on the recombinant viral nucleocapsid protein. 208 plasma samples were collected from 82 confirmed and 58 probable cases (qPCR negative but with typical manifestation). The diagnostic value of IgM was evaluated in this cohort. RESULTS: The median duration of IgM and IgA antibody detection was 5 (IQR, 3–6) days, while IgG was detected 14 (IQR, 10–18) days after symptom onset, with a positive rate of 85.4%, 92.7%, and 77.9%, respectively. In confirmed and probable cases, the positive rates of IgM antibodies were 75.6% and 93.1%, respectively. The detection efficiency by IgM ELISA is higher than that of qPCR after 5.5 days of symptom onset. The positive detection rate is significantly increased (98.6%) when combining IgM ELISA assay with PCR for each patient compared with a single qPCR test (51.9%). CONCLUSIONS: The humoral response to SARS-CoV-2 can aid in the diagnosis of COVID-19, including subclinical cases.
has issue date	2020-03-21(xsd:dateTime)
bibo:doi	10.1093/cid/ciaa310
bibo:pmid	32198501
has license	no-cc
sha1sum (hex)	702a054b29bc68d6e1e5db1ef5992c81fb4cd966
schema:url	https://doi.org/10.1093/cid/ciaa310
resource representing a document's title	Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)
has PubMed Central identifier	PMC7184472
has PubMed identifier	32198501
schema:publication	Clin Infect Dis
resource representing a document's body	covid:702a054b29bc68d6e1e5db1ef5992c81fb4cd966#body_text
is schema:about of	named entity 'quarantine' named entity 'current' named entity 'major' named entity 'Profiling' named entity 'TECHNIQUE' named entity 'VARIOUS' named entity 'POTENTIAL' named entity 'FAILURE' named entity 'TO DESCRIBE' named entity 'HEALTHCARE' named entity 'QUARANTINE' named entity 'describe' named entity 'patient' named entity 'antibody testing' named entity 'False-negative' named entity 'coronavirus' named entity '1-8' named entity 'Novagen' named entity 'HKU1' named entity 'SARS-CoV-2' named entity 'antibody response' named entity 'human plasma' named entity 'SPSS' named entity 'OC43' named entity 'COVID-19' named entity 'titration' named entity 'IgM' named entity 'San Diego' named entity 'HKU1' named entity 'immunoglobulin' named entity 'SARS-CoV-2' named entity 'subclinical' named entity 'OC43' named entity 'nucleocapsid' named entity 'chest CT' named entity '1, 2' named entity 'viruses' named entity 'IgM' named entity 'PCR' named entity 'runny nose' named entity 'rNP' named entity 'ELISAs' named entity 'epidemiology' named entity 'symptom' named entity 'detection limit' named entity 'human coronaviruses' named entity 'IgG antibodies' named entity 'coronaviruses' named entity 'gene sequences' named entity 'secondary antibody' named entity 'early diagnosis' named entity 'plasma' named entity 'IgM' named entity 'Student's t test' named entity 'clinical characteristics' named entity 'virus' named entity 'epidemic' named entity '229E' named entity 'sample collection' named entity '229E'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software